5 Oct 2015 16:41
5 October 2015
Motif Bio plc
("Motif" or the "Company")
Directors Dealings
Motif (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics was notified, on 2 October 2015 that Dr. John Stakes, Non Executive Director of Motif, purchased 100,000 ordinary shares in the Company at 60 pence per ordinary share on 2 October 2015. Accordingly, Dr. John Stakes owns 171,850 ordinary shares, representing approximately 0.16 per cent of the Company's issued share capital.
Enquiries
Motif Bio plc Graham Lumsden (Chief Executive Officer) Robert Bertoldi (Chief Financial Officer) www.motifbio.com | info@motifbio.com | |
|
| |
Zeus Capital Limited (NOMINATED ADVISER and BROKER) | +44 (0)20 3829 5000 | |
Phil Walker/Dan Bate Dominic Wilson
|
| |
Northland Capital Partners Limited (BROKER) | +44 (0) 20 7382 1100 | |
Patrick Claridge/ David Hignell John Howes/ Mark Treharne (Broking)
|
| |
Plumtree Capital Limited (FINANCIAL ADVISOR) |
+49 (0) 89 210 2280 +44 (0) 207 148 5998
+44 (0) 207 183 2493 | |
Stephen Austin
|
| |
Yellow Jersey PR Limited (FINANCIAL PR) Dominic Barretto Charles Goodwin
| +44 (0) 774 778 8221 |
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.
The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.